A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy

Epidermal growth factor receptor (EGFR) is an important therapeutic target in lung cancer. Gefitinib and erlotinib, two reversible EGFR receptor tyrosine kinases inhibitors (TKIs), have been approved for the treatment of patients with metastatic non small-cell lung cancer. Icotinib, which is a selec...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHENG, XIAO, LIU, GUAN, WANG, SHENGYE, ZHANG, YUNLI, BAO, WENLONG, DENG, DEHOU, MAO, WEIMING, FANG, MEIYU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156212/
https://www.ncbi.nlm.nih.gov/pubmed/25202368
http://dx.doi.org/10.3892/ol.2014.2386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156212/
https://www.ncbi.nlm.nih.gov/pubmed/25202368
http://dx.doi.org/10.3892/ol.2014.2386

Ejemplares similares